Imunon (Nasdaq:IMNN) - Stock Price, News & Analysis

IMNN Stock Overview

Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases.

About the company

IMNN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Highly volatile share price over the past 3 months

Earnings are forecast to decline by an average of 14.3% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

+ 2 more risks

Imunon, Inc. Competitors

OncoCyte

NasdaqCM:OCX

US$21.2m

Nascent Biotech

OTCPK:NBIO

US$15.8m

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Innovation Pharmaceuticals

OTCPK:IPIX

US$5.3m

Price History & Performance

Summary of all time highs, changes and price drops for Imunon
Historical stock prices
Current Share Price	US$1.13
52 Week High	US$2.00
52 Week Low	US$0.48
Beta	2.01
1 Month Change	39.58%
3 Month Change	97.37%
1 Year Change	-10.71%
3 Year Change	-93.42%
5 Year Change	-96.70%
Change since IPO	-99.99%

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Shareholder Returns

	IMNN	US Biotechs	US Market
7D	-26.9%	-4.7%	-3.7%
1Y	-10.7%	-2.7%	20.2%

Return vs Industry: IMNN underperformed the US Biotechs industry which returned -2% over the past year.

Return vs Market: IMNN underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement	23.1%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: IMNN's share price has been volatile over the past 3 months.

Volatility Over Time: IMNN's weekly volatility has increased from 14% to 23% over the past year.

About the Company

Founded	Employees	CEO	Website
1982	33	n/a	www.imunon.com

Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company’s lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer.

Imunon, Inc. Fundamentals Summary

How do Imunon's earnings and revenue compare to its market cap?
IMNN fundamental statistics
Market cap	US$10.57m
Earnings (TTM)	-US$19.51m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Is IMNN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMNN income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$19.51m
Earnings	-US$19.51m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.08
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did IMNN perform over the long term?

See historical performance and comparison

IMNN Stock Overview

Rewards

Risk Analysis

Imunon, Inc. Competitors

NasdaqCM:OCX

US$21.2m

OTCPK:NBIO

US$15.8m

NasdaqCM:VBLT

US$12.1m

OTCPK:IPIX

US$5.3m

Price History & Performance

Recent News & Updates

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Recent updates

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00

Full year 2021 earnings: EPS misses analyst expectations

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform

First half 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 1H 2020)

Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Celsion Corporation Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer

Celsion Corporation(NasdaqCM:CLSN) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.20 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.77 loss in FY 2019)

Celsion Corporation Announces Update on Phase I/II Ovation 2 Study